ORPHA:2086
Optic pathway glioma
Publications
1,681
88.5th percentile
Trials
20
Interventional, condition-specific
Researchers
1,081
Distinct authors in sample
Gene link
—
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
Optic pathway glioma (OPG) is a benign tumor that develop along the optic nerve (chiasm, tracts, and radiations) characterized by impairment or loss of vision and may be accompanied by diencephalic symptoms such as reduced growth and alteration in sleeping patterns. OPG are often linked to neurofibromatosis type 1 (NF1).
How rare: 1-9 / 1 000 000 — roughly one to nine people per million. In a city the size of Kolkata, perhaps a few dozen.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0016167
- UMLS:C0796418
- NCIT:C8567
Additional Mondo synonyms (7)
glioma of optic tract · glioma of the optic tract · glioma of the visual pathway · glioma of visual pathway · optic pathway glioma · optic tract glioma · visual pathway glioma
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
1,681 matched papers (1,258 in last 10 years) Source
- Phenotype characterisedPresent
23 HPO annotations (e.g. Neurofibroma; Reduced visual acuity; Abnormality of the nervous system) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
20 matched on ClinicalTrials.gov (2 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
23
Associated phenotypes · MONDO:0016167
- Neurofibroma
- Reduced visual acuity
- Abnormality of the nervous system
- Precocious puberty
- Papilledema
Showing 5 of 23 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-27
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
12
Drugs / clinical candidates · MONDO_0016167
- SELUMETINIB·phase 3
- TEMOZOLOMIDE·phase 3
- VINBLASTINE·phase 3
- CARBOPLATIN·phase 2
- ENDOSTATIN·phase 2
- ENDOSTATIN, N-TERMINAL-MGGSHHHHH·phase 2
- INTERFERON ALFA-2B·phase 2
- LENALIDOMIDE·phase 2
- NERVE GROWTH FACTOR·phase 2
- VINCRISTINE·phase 2
- CELECOXIB·phase 1
- FLUVASTATIN·phase 1
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
1,681
1,681 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
1,681 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
1,258 in the last 10 years · high confidence · 88.5th percentile (publications denominator)
Phrase hits: 1,681 · MeSH hits: 0
Who's working on it?
1,081
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Gutmann DH13 papers · 2026
Department of Neurology, Washington University School of Medicine, St Louis, Missouri, USA.
Papers in Europe PMC - 02Gupta A5 papers · 2026
Institute for Informatics, Data Science and Biostatistics, Washington University, Saint Louis, MO 63110, United States.
Papers in Europe PMC - 03Bouffet E4 papers · 2026
Division of Haematology/Oncology, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
Papers in Europe PMC - 04Chen Y4 papers · 2026
Department of Genetics, The University of Alabama at Birmingham, Alabama.
Papers in Europe PMC - 05Fisher MJ4 papers · 2024
Division of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Papers in Europe PMC - 06Hillis E4 papers · 2026
Institute for Informatics, Data Science and Biostatistics, Washington University, Saint Louis, MO 63110, United States.
Papers in Europe PMC - 07Kotch C4 papers · 2025
Division of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Papers in Europe PMC - 08Wang Y4 papers · 2026
Department of Ophthalmology, Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, P.R. China.
Papers in Europe PMC - 09Avery RA3 papers · 2026
Division of Ophthalmology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Papers in Europe PMC - 10Chatterjee A3 papers · 2026
Department of Radiation Oncology, Tata Memorial Hospital, TMC and Homi Bhabha National Institute, Mumbai, Maharashtra, India.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
20
interventional trials for this specific condition
20 interventional trials matched this specific condition name; 2 currently recruiting in our sample. 1,037 trials are registered for glioma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 9 September 2026
20 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 94.8th percentile).
high confidence · 94.8th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
20 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT04065776·RECRUITING·Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma
Confirmed·Conditions: Glioma · Pilocytic Astrocytoma · Pilomyxoid Astrocytoma · Pleomorphic Xanthoastrocytoma·Matched via name phraseBoth providers judged relevant.
- NCT05278715·RECRUITING·Modified CV Regimen in Optic Pathway Glioma
Confirmed·Conditions: Optic Glioma · Pediatric Brain Tumor, Optic Nerve Glioma·Matched via name phraseBoth providers judged relevant.
Broader category: glioma
1,037
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT03896568·RECRUITING·MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
Likely noise·Conditions: IDH1 wt Allele · Recurrent Anaplastic Astrocytoma · Recurrent Glioblastoma · Recurrent Gliosarcoma·Matched via name phraseBoth providers judged irrelevant.
- NCT07541781·RECRUITING·Sitagliptin in Recurrent/Progressive Grade 4 Glioma
Likely noise·Conditions: Glioma · Glioblastoma · Recurrent Glioma · Recurrent Glioblastoma·Matched via name phraseBoth providers judged irrelevant.
- NCT06528691·RECRUITING·Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors
Uncertain·Conditions: High Grade Glioma · CNS Tumor·Matched via name phraseAt least one provider returned uncertain or parent-category.
- NCT05345002·RECRUITING·All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
Likely noise·Conditions: Glioma · IDH Mutation · Astrocytoma · Oligodendroglioma·Matched via name phraseBoth providers judged irrelevant.
- NCT07644312·NOT YET RECRUITING·Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG and DIPG
Likely noise·Conditions: High Grade Glioma · Diffuse Intrinsic Pontine Glioma · WHO Grade 3 Glioma · WHO Grade 4 Glioma·Matched via name phraseBoth providers judged irrelevant.
- NCT07488780·NOT YET RECRUITING·Language Network Prehab Via fMRI Neurofeedback
Uncertain·Conditions: Glioma · Glioma Surgery·Matched via name phraseAt least one provider returned uncertain or parent-category.
- NCT04870944·RECRUITING·CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
Likely noise·Conditions: Diffuse Midline Glioma, H3 K27-Altered · Metastatic Malignant Neoplasm in the Central Nervous System · Recurrent Diffuse Intrinsic Pontine Glioma · Recurrent Diffuse Midline Glioma, H3 K27-Altered·Matched via name phraseBoth providers judged irrelevant.
- NCT07004075·NOT YET RECRUITING·FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration
Uncertain·Conditions: Low-grade Glioma · Pediatric Low-grade Gliomas · pLGG With BRAF Alteration·Matched via name phraseAt least one provider returned uncertain or parent-category.
- NCT07551336·RECRUITING·Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma
Likely noise·Conditions: Malignant Glioma · High-Grade Gliomas · Glioblastoma · Recurrent High-Grade Gliomas·Matched via name phraseBoth providers judged irrelevant.
- NCT07678684·RECRUITING·A Study of HF1K16 Combined With Bevacizumab in Patients With Recurrent or Progressive Glioma
Uncertain·Conditions: Glioma · Adult·Matched via name phraseAt least one provider returned uncertain or parent-category.
- NCT07109362·NOT YET RECRUITING·ERP-Based Research on the Modulation of Remimazolam on Working Memory and Brain Network Mechanisms in Glioma Patients
Likely noise·Conditions: Remimazolam Mild Sedation · Healthy Brain and Glioma Brain·Matched via name phraseBoth providers judged irrelevant.
- NCT07223034·RECRUITING·A Study of 177Lu-PSMA-617 in People With Gliomas
Likely noise·Conditions: Glioma · Diffuse Astrocytoma, IDH-Wildtype (Grade 2-4) · Glioblastoma, IDH-wildtype · Diffuse Midline Glioma, H3 K27-Altered·Matched via name phraseBoth providers judged irrelevant.
- NCT06161519·RECRUITING·PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
Uncertain·Conditions: Glioma · Medulloblastoma · Ependymoma · Glioblastoma·Matched via name phraseAt least one provider returned uncertain or parent-category.
- NCT07710131·NOT YET RECRUITING·Neurocognitive Assessment CNSL and LGG
Uncertain·Conditions: PCNSL · Brain Tumor · Cognitive Dysfunction · IDH Mutation·Matched via name phraseAt least one provider returned uncertain or parent-category.
- NCT06860594·RECRUITING·Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
Likely noise·Conditions: Astrocytoma, IDH-Mutant, Grade 2 · Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-Mutant · Recurrent Adult Diffuse Midline Glioma, H3 K27-Mutant · Recurrent Astrocytoma, IDH-Mutant·Matched via name phraseBoth providers judged irrelevant.
Observational and natural-history studies
1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
None of the matched observational studies is currently listed as recruiting.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 2 · after dedupe 2 · already on CT.gov 0 · kept 1 · parent 0 · uncertain 0 · dropped 1 · fetched 2026-07-27
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Optic pathway glioma — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Optic pathway glioma" OR "glioma of optic tract" OR "glioma of the optic tract" OR "glioma of the visual pathway" OR "glioma of visual pathway" OR "optic tract glioma" OR "visual pathway glioma"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Optic pathway glioma" OR "glioma of optic tract" OR "glioma of the optic tract" OR "glioma of the visual pathway" OR "glioma of visual pathway" OR "optic tract glioma" OR "visual pathway glioma"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 20 interventional · 1 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"glioma"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-26T02:05:05.717Z
